Disclaimer: Coverage depends on the NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service.

| Description | Brand Name | Category | * AC OP | *CAH OP | * P | *MW | * NP | *OPH | * POD | *DC | *HI | * IDTF | *ASC | Special Instructions |
|---------------------------------------|---------------------|-----------------|------------|------------|-----|-----|------|------|-------|-----|-----|--------|------|--|
| Allopurinal Sodium 500 mg | Aloprim Zyloprim | | Х | Х | X | | | | | | | | | Effective 10/1/2015 ICD-10 diagnosis codes C50.911, C50.912, C50.919, E79.0, R78.71, R78.79, R78.89, R79.0, R79.89 or R79.9 plus ICD-10-CM for Neoplasm required on claim. Drug must be billed with the code for Chemotherapy. ICD-9 codes 174.9 or 790.6 plus ICD-9-CM for Neoplasm required on claim. Drug must be billed with the code for Chemotherapy. |
| 17 Alpha- hydroxy- progesterone | | | | | х | Х | Х | | | | | | | Closed 12/31/11. See J1725 after this date. See Q2042, effective 7/1/11. Effective 1/1/07. Cost invoice required with claim. Pay lesser of billed charges and cost invoice. ICD-9 code V23.41 required on claim form. Service limit is one per week at 16-36 weeks gestation. |
| Aminocaproic Acid 250mg | | | х | Х | | | | | | | | | | |
| Apomorphine HCI 10mg | Apokyn | | Х | Х | | | | | | | | | | Deleted from list effective 12/31/06. See J0364. |
| Aztreonam 500 mg | Azactam | Antibiotic | х | х | Х | | Х | | Х | | | | | |
| Betametha- sone acetate | | Anti-inflam. | Х | Х | Х | | | | | | | | | Cost invoice required with claim. Pay lesser of billed charges or cost invoice. |
| Bevacizumab 1.25 mg. | Avastin | Anti-neoplastic | | | | | | x | | | | | | Effective 10/1/2015 ICD-10 diagnosis codes E08.311, E08.319, E08.3211, E08.3212, E08.3213, E08.3291, E08.3292, E08.3293, E08.3311, E08.3312, E08.3313, E08.3391, E08.3392, E08.3393, E08.3411, E08.3412, E08.3413, E08.3491, E08.3492, E08.3493, E09.311, E09.319, E09.3211, E09.3212, E09.3213, E09.3291, E09.3292, E09.3293, E09.3311, E09.3312, E09.3313, E09.3391, E09.3392, E09.3393, E09.3411, E09.3412, E09.3413, E09.3491, E09.3492, E09.3493, E10.311, E10.319, E10.3211, E10.3212, E10.3213, E10.3311, E10.3312, E10.3313, E10.3411, E10.3412, E10.3413, E10.3511, E10.3512, E10.3513, E11.311, E11.3212, E11.3213, E11.3213, E11.3311, E11.3312, E11.3313, E11.3314, E11.3412, E11.3413, E11.3412, E11.3413, E11.3511, E11.3512, E11.3513, E11.3513, E11.3411, E11.3412, E11.3413, E11.349, E11.3511, E11.3512, E11.3513, E11.3513, E11.3314, E11.3412, E11.3413, E11.349, E11.3511, E11.3512, E11.3513, E11.3513, E11.3314, E11.3412, E11.3413, E11.349, E11.3511, E11.3512, E11.3513, H35.3120, H35.3210, H35.3211, H35.3212, H35.3213, H35.32213, H35.3221, H35.3233, H35.3221, H35.3233, Effective 10/1/17]; H35.351 - H35.353, H35.359, H35.72 - H35.723, H35.729, H35.81, H35.82 or H40.89. Effective 1/1/07 to O |
| Bretylium 0.25 mg | Tosylate | Anti-arrhythmic | х | Х | x | | Х | | | | | | | Effective 10/1/2015 ICD-10 diagnosis codes E08.311, E08.319, E08.3211, E08.3212, E08.3213, E08.3291 E08.3292, E08.3293, E08.3311, E08.3312, E08.3313, E08.3391, E08.3392, E08.3393, E08.3411, E08.3412, E08.3413, E08.3491,E08.3492, E08.3493, E09.311, E09.3 |

Disclaimer: Coverage depends on the NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service.

| Description | Brand Name | Category | * AC OP | *CAH OP | * P | *MW | * NP | *OPH | * POD | *DC | *HI | * IDTF | *ASC | Special Instructions |
|---|------------------------------|---------------------------|------------|------------|-----|-----|------|------|-------|-----|-----|--------|------|---|
| Bumetanide 0.25 mg | Bumex | Antihyper- tensive | Х | Х | Х | | Х | | | | | | | |
| Bupivicaine 0.75%, 1 ml | Marcaine Sensor- caine | Peripheral Nerve Block | Х | Х | Х | | Х | | | | | | | 0.75% / 10ml allowed when billed with 62310, 62311, 62318, 62319, 64400 - 64530. Not payable when billed with other procedures. |
| Cefotetan | Cefotan | Antibiotic | Х | Х | | | | | | | | | | Cost invoice with NDC required with claim. Pay lesser of billed charges and cost invoice. |
| Cimetidine HCI | Tagamet | Anti-histamine | Х | Х | Х | | Х | | | | | | | Effective 10/1/2015 ICD-10 diagnosis codes R11.0, R11.2, or R11.10 - R11.12 |
| 150 mg | | | | | | | | | | | | | | ICD-9 codes 787.01, 787.02 or 787.03 required on claim form. |
| Clavulanate Potassium Ticarcillin Disodium 0.1 - 3G | Timentin | Antibiotic | х | x | x | | х | | X | | | | | |
| Clindamycin Phosphate 150 mg | Cleocin Clindamax | Antibiotic | Х | Х | х | | Х | | х | | | | | |
| Dantrolene Sodium 20mg | Dantrium | Antidote | Х | Х | Х | | Х | | | | | | | Cost invoice with NDC required with claim. Pay lesser of billed charges and cost invoice. |
| Dextrose 50% 50ml | | | Х | Х | х | | Х | | | | | | | |
| Diltiazem HCI 5mg | Cardizem | Antianginal | Х | Х | х | | Х | | | | | | | |
| Edrophonium Chloride 10mg | Tensilon Reverso | Antidote | Х | Х | х | | Х | | | | | | | Effective 10/1/2015 ICD-10 diagnosis codes G70.00 or G70.01 ICD-9 358.00 - 358.01 required on claim form. |
| Enalaprilat 1.25mg | Vasotec | Antihyper- tensive | Х | Х | х | | | | | | | | | |
| | Brevibloc | Anti-arrhythmic | Х | х | х | | х | | | | | | | Effective 10/1/2015 ICD-10 diagnosis code I49.8 or R00.1 ICD-9 427.89 required on claim form. |
| Ethacrynate Sodium 50 mg | Edecrin | Diuretic | Х | Х | х | | Х | | | | | | | Cost invoice required with claim. Pay lesser of billed charges and cost invoice. |
| Famotidine 10 mg | Pepcid | | Х | Х | х | | Х | | | | | | | |
| Flumazenil 0.1 mg | Romazicon Mazicon | Antidote | Х | Х | Х | | Х | | | | | | | Effective 10/1/2015 ICD-10 diagnosis codes T50.901A - T50.904A ICD-9 977.9 required on claim form. |
| Folic Acid 5mg | Folate | | Х | Х | Х | | Х | | | | | | | |
| Glycopyrrolate 0.2 mg | Robinul | Antichole- nergic | X | X | X | | X | | | | | | | |
| Isoproterenol HCI 0.2 mg | Isuprel | Bronchodil-ator | Х | х | Х | | х | | | | | | | Cost invoice with NDC required with claim. Pay lesser of billed charges and cost invoice. |
| | Trandate Normo-dyne | | Х | Х | Х | | Х | | | | | | | Effective 10/1/2015 ICD-10 diagnosis code I10 Covered for IV in office only. ICD-9 code 401.0 required on claim form. |

Disclaimer: Coverage depends on the NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service.

| Description | Brand Name | Category | * AC OP | *CAH OP | * P | *MW | * NP | *OPH | * POD | *DC | *HI | * IDTF | *ASC | Special Instructions |
|--------------------------------------|---------------------------------|--|------------|------------|-----|-----|------|------|-------|-----|-----|--------|------|--|
| Lidocaine 1 ml | Hume | | X | X | Х | | | | | | | | | Covered separately when billed on same day as 62310, 62311, 62318, 62319, 64400-64484, 64505-64530. Not payable when billed with other procedures. |
| Metoprolol Tartrate 1 mg | Lopressor | Antihyper- tensive | Х | Х | Х | | | | | | | Х | | Covered only when given IV with Dobutamine J1250 during Dobutamine Stress Test. J3490 & J1250 must be billed on same date of service. |
| 500 mg | Flagyl | Amebicide | х | х | х | | Х | | | | | | | |
| | Dynacin Minocin | Antibiotic | х | Х | х | | Х | | Х | | | | | Cost invoice with NDC required with claim. Pay lesser of billed charges and cost invoice. |
| Morrhuate Sodium 50mg | | Sclerosing Agent | х | Х | х | | | | | | | | | Bill with CPT codes 43204 and 46500 |
| Nafcillin Sodium 1 g | Nallpen | Anitbiotic | х | Х | х | | Х | | Х | | | | | |
| mg | Nitrostat | Anti-anginal | х | Х | х | | Х | | | | | | | |
| Pantoprazole Sodium 40mg | Protonix | Gastric Acid Secretion Inhibitor | х | X | х | | Х | | | | | | | |
| Potassium Acetate 2 mEg | Klor-Con | Electrolyte Supple-ment | | | Х | | Х | | | | | | | |
| Rifampin 600 mg | Rifacin Rimactane | Antibiotic | Х | Х | х | | Х | | | | | | | |
| Sodium Acetate 2 mEg | | Alkalinizing Agent | | | х | | Х | | | | | | | |
| Sodium Bicarbonate 8.4%, 50 ml | | Alkalini-zing Agent | | | х | | Х | | | | | | | |
| Valproate Sodium 100 mg | Depacon | | X | X | × | | x | | | | | | | Effective 10/1/2015 ICD-10 diagnosis codes G40.001, G40.009, G40.011, G40.019, G40.101, G40.109, G40.111, G40.119, G40.201, G40.209, G40.211, G40.219, G40.301, G40.309, G40.311, G40.319, G40.401, G40.409, G40.411, G40.419, G40.501, G40.509, G40.801 - G40.804, G40.811 - G40.814, G40.821 - G40.824, G40.89, G40.901, G40.909, G40.911, G40.919, G40.A01, G40.A09, G40.A11, G40.A19, G40.B01, G40.B09, G40.B11 or G40.B19 ICD-9 code 345.00 - 345.91 required on claim form. |
| Vasopressin 20 u | Pitressin | Antidiuretic | Х | Х | х | | х | | | | | | | |
| Verapamil HCI 2.5 mg | Calan Calan SR Isoptin SR | Anti-anginal | Х | Х | Х | | Х | | | | | | | |
| Ferumoxytol Injection 510 mg. | Feraheme | Iron therapy | Х | Х | Х | | Х | | | Х | | | | Closed 12/31/09(not billable with J3490). See Q0138 & Q0139 afer this date. Effective 6/30/09. Claim must be billed with ICD-9 codes 585.1- 585.9 and 280.0 - 280.9. 1 unit = 1 vial. |

Disclaimer: Coverage depends on the NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service.

| Description | Brand Name | Category | * AC OP | *CAH OP | * P | *MW | * NP | *OPH | * POD | *DC | *HI | * IDTF | *ASC | Special Instructions |
|--|---------------------|-----------------------------|------------|------------|-----|-----|------|------|-------|-----|-----|--------|------|--|
| Testosterone pellet, 75 mg. | Testopel | Hormone replace- ment | Х | х | х | | Х | | | | | | | Effective 10/1/2015 ICD-10 diagnosis codes E29.1, E29.8, or E29.9 Effective 1/1/09. Restricted to ICD-9 codes 257.2, 257.8, 257.9. Minimum age 18. 1 unit = 1 pellet. |
| Regadenoson 0.1 mg. | Lexiscan | Vasodilater | Х | Х | Х | | | | | | | | | Closed 12/31/08. See J2785 after this date. Effective 10/1/08. Cost invoice with NDC required. |
| Pralatrexate injection | Folotyn | Metabolic inhibitor | Х | Х | х | | | | | | | | | Closed 12/31/10. See J9307 afer this date. Outpatient hospital must use C9259, effective 4/1/10 - 12/31/10. Effective 9/25/09. Cost inovoice with NDC required. Restricted to ICD-9 codes 202.70 - 202.78. Minimum age restriction of 18 years. |
| Remifentanil HCI | Ultiva | Anesthetic/Anal gesic | Х | Х | | | | | | | | | | Effective 1/1/09. Cost invoice with NDC required. |
| Lacosamide 1 mg. injection | Vimpat | Anti-convulsive | x | X | | | | | | | x | | | Effective 10/1/2015 ICD-10 diagnosis codes G40.001, G40.009, G40.011, G40.019, G40.101, G40.109, G40.111, G40.119, G40.201, G40.209, G40.211, G40.219, G40.301, G40.309, G40.311, G40.319, G40.401, G40.409, G40.411, G40.419, G40.501, G40.509, G40.801 - G40.804, G40.811 - G40.814, G40.821 - G40.824, G40.89, G40.901, G40.909, G40.911, G40.919, G40.A01, G40.A09, G40.A11, G40.A19, G40.B01, G40.B09, G40.B11 or G40.B19 Effective 1/1/10. Cost invoice with NDC required. ICD-9 restriction of 345.00 - 345.91. Minimum age restriction of 17 years. Service limit of 400 mg. daily applies. |
| Paliperidone palmitate 1 mg. injection | Invega Sustenna | Anti-psychotic | Х | Х | Х | | | | | | х | | | Closed 12/31/10. See J2426 after this date. Outpatient hosptial must use C9255, effective 1/1/10 - 12/31/10. Effective 1/1/10. Cost invoice with NDC required. ICD-9 restriction of 295.00 - 295.95. Minimum age restriction of 18 years. Service limit of 234 mg. daily applies. |
| Dexametha- sone intravitreal implant | Ozurdex | Anti- inflammatory | х | X | | | | х | | | | | | Closed 12/31/10. See J7312 after this date. Outpatient hospital must use C9256, effective 1/1/10 - 12/31/10. Effective 1/1/10. Cost invoice with NDC requried. ICD-9 restriction of 362.83 and 362.35, or 362.83 and 362.36. <u>New ICD-9 diagnosis 363.00 - 363.08 effective 9/24/10.</u> Minimum age restriction of 16 years. |
| C1 esterase inhibitor (human) injection | Berinert | Protein C-1 inhibitor | Х | Х | х | | Х | | | | Х | | | Closed 12/31/10. See J0597 after this date. Effective 10/9/09(FDA approval). Cost invoice with NDC required. ICD-9 restriction of 277.6. Minimum age restriction of 12 years. |
| Olanzapine pamoate LA, injection | Zyprexa Relprevv | Anti-psychotic | Х | Х | х | | Х | | | | Х | | | Closed 12/31/10. See J2358 after this date. Effective 12/11/09(FDA approval). Cost invoice with NDC required. ICD-9 restriction of 295.00 - 295.95. Minimum age restriciton of 18 years. Service limit of 405 mg. in 28 days applies. |
| Ofatumumab, injection | Arzerra | Anti-neoplastic | | | Х | | | | | | | | | Closed 12/31/10. See J9302 after this date. Effective 10/26/09(FDA approval). Cost invoice with NDC required. ICD-9 restriction of 204.10 - 204.12. Minimum age restriction of 18 years. Service limit of 2000 mg. in 7 days applies. |
| Collagenase clostridium histolyticum, injection | Xiaflex | Enyzmatic | х | Х | Х | | х | | | | | | | Closed 12/31/10. See J0775 after this date. Outpatient hospital must use C9266, effective 7/1/10 - 12/31/10. Effective 2/2/10(FDA approval). Cost invoice with NDC required. ICD-9 restriction of 728.6. Minimum age restriction of 18 years. |
| Telavancin, injection | Vibativ | Anti-bacterial | Х | Х | Х | | х | | | | Х | | | Closed 12/31/10. See J3095 after this date. Outpatient hospital must use C9258, effective 4/1/10 - 12/31/10. Effective 9/11/09(FDA approval). Cost invoice with NDC required. ICD-9 restriction of 680.0 - 686.9 and 041.0 - 041.9. Minimum age restriction of 18 years. |

Disclaimer: Coverage depends on the NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service.

| • | Brand Name | Category | * AC OP | *CAH OP | * P | *MW | * NP | *OPH | * POD | *DC | *HI | * IDTF | *ASC | Special Instructions |
|--|---------------|--------------------------|------------|------------|-----|-----|------|------|-------|-----|-----|--------|------|--|
| Ecallantide, injection | Kalbitor | Kallikrein inhibitor | Х | Х | х | | Х | | | | Х | | | Closed 12/31/10. See J1290 after this date. Outpatient hospital must use C9263, effective 4/1/10 - 12/31/10. Effective 11/27/09(FDA approval). Cost invoice with NDC required. ICD-9 restriction of 277.6. Minimum age restriction of 16 years. Service limit of 30 mg. per day applies. |
| Alglucosidase alfa, injection | Lumizyme | Enzymatic | х | х | х | | | | | | | | | Closed 12/31/11. See J0221. Effective 5/24/10(FDA approval). Cost invoice with NDC required. ICD-9 restriction of 271.0. Minimum age restriction of 8 years and above. Outpatient hospital must use C9277, effective 1/1/11. |
| Ustekinumab, injection | Stelara | Antipsoriatic | Х | х | Х | | | | | | | | | Closed 12/31/10. See J3357 after this date. Effective 9/25/09(FDA approval). Cost invoice with NDC required. ICD-9 restriction of 696.0 - 696.8. Minimum age restriction of 18 and above. |
| Denosumab, injection | Prolia | Osteoporotic | х | х | х | | | | | | | | | Closed 12/31/11. See J0897. Effective 6/1/10(FDA approval). Cost invoice with NDC required. ICD-9 restriction of 733.01. Service limit of 60 mg. twice yearly(every six months) applies. Outpatient hospital must use C9272, effective 10/1/10. |
| Tocilizumab, injection | Actemra | Immunologic | Х | х | X | | | | | | | | | Closed 12/31/10. See J3262. Effective 1/8/10(FDA approval). Cost invoice with NDC required. ICD- 9 restriciton of 714.0 - 714.2. Minimum age restriction of 16 years and above. Service limit of 800 mg. once monthly(every 28 days) applies. |
| von Willebrand/Fact or VIII complex (human) | Wilate | Coagulation factor | х | X | х | | | | | | | | | Closed 12/31/10. See J7184 after this date. Outpatient hospital must use C9267, effective 7/1/10 - 12/31/10. Effective 12/4/09(FDA approval). Cost invoice with NDC required. Submit physician's order with claim. ICD-9 restriction of 286.4. Minimum age restriction of 5 years and above. |
| Capsaicin 8% patch | Qutenza | Analgesic | х | х | х | | | | | | | | | Closed 12/31/10. See J7335 after this date. Outpatient hospital must use C9268, effective 7/1/10 - 12/31/10. Effective 11/16/09(FDA approval). Cost invoice with NDC required. ICD-9 restriction of 053.19. Minimum age restriction of 18 years and above. Service limit not to exceed once every 3 months. |
| Cabazitaxel, injection | Jevtana | Antineoplastic | х | х | Х | | | | | | | | | Closed 12/31/11. See J9043. Effective 6/17/10(FDA approval). Cost invoice with NDC required. ICD-9 restriction of 185.0. Outpatient hospital must use C9276, effective 1/1/11. |
| Sodium hyaluronate, injection | Synvisc 1 | Viscosuppleme ntation | Х | х | х | | х | | | | | | | Closed 12/31/09. See J7325 after this date. Effective 2/26/09(FDA approval). Cost invoice required. ICD- 9 restriction of 715.00 - 715.98 or 716.00 - 716.99. Service limit of 1 injection each knee in 6 months(4 injections total per year). |
| Injection, romidepsin, 1 mg | Istodax | Antineoplastic | х | X | x | | | | | | x | | | Closed 12/31/10. See J9315 after this date. Outpatient hospital must use C9265, effective 7/1/10 - 12/31/10. Effective 11/5/09(FDA approval). Physician provider type is Oncology specialty only. Cost invoice with NDC required. Restricted to ICD-9 diagnosis 202.10 - 202.28. Restricted to age 18 and above. |
| Injection, denosumab, 120 mg | Xgeva | Osteoporotic | х | Х | x | | | | | | х | | | Closed 12/31/11. See J0897. Effective 6/1/10(FDA approval). Cost invoice with NDC required. ICD-9 restriction of 162.0 - 162.9, 174.0 - 174.9, 175.0 - 175.9, 185, 189.0, 189.1, 193, 198.5, 733.01 - 733.19 for Hospital and Physician. ICD-9 restriction of 733.01 - 733.19 only for Home infusion provider. Minimum age restriction 18 years and above. Service limit of 120 mg. (1 unit) monthly applies. Outpatient hospital must use C9272, effective 10/1/10. |
| Injection, velaglucerase alfa, 100 u. | Vpriv | Enzymatic | Х | Х | х | | | | | | | | | Closed 12/31/10. See J3385 after this date. Outpatient hospital must use C9271, effective 10/1/10 - 12/31/10. Effective 2/26/10(FDA approval). Cost invoice with NDC requried. ICD-9 restriction of 272.7. Minimum age restriction of 4 years. Service limit of 1650 units per month applies. |
| Injection, eribulin mesylate, 1 mg. | Halaven | Antineoplastic | Х | Х | х | | | | | | | | | Closed 12/31/11. See J9179. Effective 11/15/10(FDA approval). Cost invoice with NDC required. ICD-9 restriction of 174.0 - 175.9 or 198.81. Minimum age restriction of 18 years and above. Service limit of 8 mg. in 21 days applies. Outpatient hospital must use C9280, effective 4/1/11. |

Disclaimer: Coverage depends on the NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service.

| Description | Brand Name | Category | * AC OP | *CAH OP | * P | *MW | * NP | *OPH | * POD | *DC | *HI | * IDTF | *ASC | Special Instructions |
|---|---------------|--------------------------------|------------|------------|-----|-----|------|------|-------|-----|-----|--------|------|---|
| Injection, pegloticase, 1 mg. | Krystexxa | Hyperuricemic | х | Х | x | | | | | | Х | | | Closed 12/31/11. See J2507. Effective 9/14/10(FDA approval). Cost invoice with NDC required. ICD-restriction of 274.0 - 274.89. Minimum age restriction of 18 years and above. Service limit of 16 mg. monthly applies. Outpatient hospital must use C9281, effective 4/1/11. |
| Injection, ceftaroline fosamil, 10 mg. | Teflaro | Antibacterial | Х | х | х | | | | | | Х | | | Closed 12/31/11. See J0712. Effective 10/29/10(FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 041.00 - 041.89 or 482.0 - 482.89. Minimum age restriction of 18 years and above. Service limit of 1200 mg. daily applies. Outpatient hospital must use C9282, effective 4/1/11. |
| Injection, belimumab | Benlysta | Immunologic | х | х | х | | | | | | Х | | | Closed 12/31/11. See J0490. Effective 3/10/11(FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 710.0. Minimum age restriction of 16 years. Service limit of 2600 mg. monthly applies. |
| Alpha-1 Proteinase inhibitor (Human) | Glassia | Enzymatic | х | X | Х | | | | | | × | | | Closed 12/31/11. See J0257. Effective 7/1/10(FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 492.8. Minimum age restriction of 16 years. Service limit of 8200 mg. weekly applies. |
| Injection, sipuleucel-T | Provenge | Antineoplastic | Х | х | Х | | | | | | Х | | | Closed 6/30/11. See Q2043. Effective 4/29/10(FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 185. Minimum age restriction of 18 years. Service limit of 1 infusion bag every two weeks. |
| Hemophilic Factor XIII (Human) | Corifact | Anti-hemophilic | Х | х | Х | | | | | | Х | | | Closed 12/31/11. See J7180. Effective 2/14/11(FDA approval). Cost invoice with NDC required. ICD-9 restriction of 286.3. |
| Injection, ipilimumab | Yervoy | Antibody | X | X | Х | | | | | | Х | | | Closed 12/31/11. See J9228. Effective 3/25/11(FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 154.2, 154.3, 172.0 - 172.9, 184.0 - 184.4, 187.1 - 187.9, 196.0 - 196.9, 197.0 - 197.8, 198.0 - 198.8. Minimum age restriction of 16 years. Service limit of 400 mg. every 21 days applies. Out patient hospital must use C9284, effective 7/1/11. |
| Patch, lidocaine 70 mg., tetracaine 70 mg. | Synera | Local Anesthetic | | | Х | | | | | | | | | Effective 7/1/11. Cost invoice with NDC required. Outpatient hospital must use C9285, effective 7/1/11. |
| Injection, belatacept 250 mg. | Nulojix | Organ rejection prophylaxis | Х | Х | х | | | | | | | | | Closed 12/31/12. See J0483 after this date. Effective 6/15/11. Cost invoice with NDC required. Must bill with V42.0 Minimum age restriction of 18 years. Service limit of 1350 mg. per dose applies. Outpatient hospital must use C9286, effective 10/1/11. |
| Injection, brentuximab vedotin 1 mg. | Adcetris | Antineoplastic | х | Х | Х | | | | | | х | | | Closed 12/31/12. See J9042 after this date. Effective 8/19/11(FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 200.60 - 200.68 or 201.00 - 201.98. Minimum age restriction of 18 years. Service limit of 180 mg. per day applies. Outpatient hospital must use C9287, effective 1/1/12. |
| Injection, asparaginase (Erwinia chrysanthemi) | Erwinaze | Antineoplastic | x | Х | Х | | | | | | Х | | | Closed 12/31/12. See J9019 after this date. Effective 11/18/11(FDA approval). Cost invoice with NDC required. ICD-9 restriction of 204.00 - 204.02. Outpatient hospital must use C9289, effective 4/1/12. |
| Injection, intravitreal, aflibercept, 2 mg. | Eylea | Neovascular (AWD) | х | Х | Х | | | | | | | | | Closed 6/30/12. See Q2046 after this date. Effective 11/18/11(FDA approval). Cost invoice with NDC required. ICD-9 restriction of 362.52. Minimum age restriction of 16 years. Service limit of 4 mg. weekly applies. Outpatient hospital must use C9291, effective 4/1/12. |

Disclaimer: Coverage depends on the NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service.

| Description | Brand Name | Category | * AC OP | *CAH OP | * P | *MW | * NP | *OPH | * POD | *DC | *HI | * IDT | F *A | SC | Special Instructions |
|--|---------------|--|------------|------------|-----|-----|------|------|-------|-----|-----|-------|------|----|--|
| Injection, peginesatide | Omontys | Erythropoiesis stimulating agent | | | | | | | | Х | | | | | Closed 6/30/12. See Q2047 after this date. Effective 3/27/12(FDA approval). Cost invoice with NDC required. ICD-9 restriction of 285.21 and 585.6. Minimum age restriction of 16 years. |
| Injection, taliglucerase alfa, 200 u. | Elelyso | Enzymatic | Х | Х | х | | | | | | | | | | Closed 12/31/13. See J3060 after this date. Effective 5/1/12(FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 272.7. Minimum age restriction of 16 years. Service limit of 41 units every two weeks applies. Outpatient hospital must use C9294, effective 1/1/13. |
| Injection, pertuzumab, 420 mg. | Perjeta | Anti-neoplastic | Х | Х | х | | | | | | | | | | Closed 12/31/13. See J9306 after this date. Effective 6/8/12(FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 174.0 - 175.9. Minimum age restriction of 16 years. Service limit of 2 units every three weeks applies. Outpatient hospital must use C9292, effective 10/1/12. |
| Injection, carfilzomib 60 mg. | Kyprolis | Anti-neoplastic | Х | х | х | | | | | | | | | | Closed 12/31/13. See J9047 after this date. Effective 7/20/12(FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 203.02. Minimum age restriction of 16 years. Outpatient hospital must use C9295, effective 1/1/13. |
| Injection, ziv- aflibercept 25 mg. | Zaltrap | Anti-neoplastic | х | Х | х | | | | | | | | | | Closed 12/31/13. See J9400 after this date. Effective 8/3/12(FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 153.0 - 153.9, 154.0, 154.1, or 154.8. Minimum age restriction of 16 years. Service limit of 550 mg. per 14 days applies. Outpatient hospital must use C9296, effective 1/1/13. |
| Injection, omacetaxine mepesuccinate 0.01 mg. | Synribo | Anti-neoplastic | Х | Х | х | | | | | | | | | | Closed 12/31/13. See J9262 after this date. Effective 10/26/12(FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 205.10 - 205.12. Minimum age restriction of 16 years. Outpatient hospital must use C9297 after 4/1/13. |
| Injection, ocriplasmin intravitreal, 2.5 mg. | Jetrea | Ophthalmic | Х | х | | | | Х | | | | | | | Closed 12/31/13. See J7316 after this date. Effective 10/17/12(FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 379.27. Minimum age restriction of 16 years. Outpatient hospital must use C9298 after 4/1/13. |
| Pooled plasma, human, solution for IV | Octaplas | Blood product | Х | Х | х | | | | | | | | | 1 | Effective 10/1/2015 ICD-10 diagnosis codes D68.32, D68.4 or M31.1 Effective 1/17/13(FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 286.7 or 446.6. Minimum age restriction of 16 years. |
| Injection, ado- traztuzumab emtansine | Kadcyla | Antineoplastic | Х | Х | х | | | | | | | | | (| Closed 12/31/13. See J9354 after this date. Effective 2/22/13(FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 174.0 - 174.9 or 175.0 - 175.9. Minimum age restriction of 16 years. Outpatient hospital must use C9131 after 7/1/13. |
| Intrauterine, Levonorgestrel, 13.5 mg. | Skyla | Contraceptive | Х | Х | Х | Х | х | | | | | | | i | Closed 12/31/13. See J7301. See Q0090, effective 7/1/13. Effective 1/9/13(FDA approval). Cost invoice with NDC required. Minimum age restriction of 16 years. Service limit of 1 insertion per 3 year period. |
| Injection, Radium Ra-223 dichloride | Xofigo | Antineoplastic | Х | Х | Х | | | | | | | | | l | Effective 10/1/2015 ICD-10 diagnosis codes C61, C79.51, or C79.52 Effective 5/15/13 (FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 185 or 198.5. |
| Injection, Coagulation factor IX, (recombinant) | Rixubis | Antihemophilic | X | Х | х | | | | | | | | | | Closed 12/31/14. See J7200 after this date. Effective 6/26/13(FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 286.1. Minimum age restriction removed, effective 9/12/14. |

Disclaimer: Coverage depends on the NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service.

| Description | Brand Name | Category | * AC OP | *CAH OP | * P | *MW | * NP | *OPH | * POD | *DC | *HI | * IDTF | *ASC | Special Instructions |
|--|-----------------|------------------------|------------|------------|-----|-----|------|------|-------|-----|-----|--------|------|--|
| Botulinim Antitoxin Heptavalent(A, B, C, D, E, F, G), equine | BAT | Antitoxin | X | x | x | | | | | | | | | Effective 10/1/2015 ICD-10 diagnosis codes A05.1 or A48.51 Effective 3/22/13 (FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 005.1 or 040.41. |
| Injection, Prothrombin Complex concentrate(hu man) | Kcentra | Coagulant | x | х | x | | | | | | | | | Effective 10/1/2015 ICD-10 diagnosis code D68.32 or D68.4 Effective 4/29/13(FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 286.7. Minimum age restriction of 16 years. |
| Injection, ferric carboxymaltose | Injectafer | Iron therapy | х | х | х | | | | | | | | | Closed 6/30/14. See Q9970 after this date. Effective 7/25/13(FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 280.1 - 280.9. Minimum age restriction of 16 years. Service limit of 750 mg. per dose (15 ml. vial) applies. Outpatient hospital must use C9441 after 1/1/14. |
| Injection, tbo- filgrastim, 5 mcg. | Granix | Leukocyte stimulant | Х | Х | х | | | | | | | | | Effective 10/1/2015 ICD-10 diagnosis codes D70.8 Effective 8/29/12 (FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 288.09. Minimum age restriction of 16 years. |
| Injection, golimumab, 12.5 mg. | Simponi Aria | TNF inhibitor | x | x | X | | x | | | | | | | Effective 10/1/2015 ICD-10 diagnosis codes M05.711, M05.712, M05.719, M05.721, M05.722, M05.729, M05.731, M05.732, M05.739, M05.741, M05.742, M05.749, M05.751, M05.752, M05.759, M05.761, M05.762, M05.769, M05.811, M05.812, M05.819, M05.821, M05.822, M05.829, M05.831, M05.832, M05.839, M05.841, M05.842, M05.849, M05.851, M05.852, M05.859, M05.861, M05.862, M05.869, M06.071, M06.072, M06.079, M06.211, M06.212, M06.219, M06.221, M06.222, M06.229, M06.231, M06.232, M06.239, M06.241, M06.242, M06.249, M06.251, M06.252, M06.259, M06.261, M06.262, M06.269, M06.811, M06.812, M06.821, M06.822, M06.829, M06.831, M06.832, M06.841, M06.842, M06.851, M06.852, M06.859, M06.861, M06.862, M06.869, M06.871, M06.872, M06.879 or M06.9 Effective 7/18/13 (FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 714.0. Minimum age restriction of 18 years. |
| Injection, vinCRISine sulfate, liposomal, 0.16 mg. | Marqibo | Antineoplastic | х | x | x | | | | | | | | | Effective 10/1/2015 ICD-10 diagnosis codes C91.00 - C91.02, C91.10 - C91.12, C91.30 - C91.32, C91.50 - C91.52, C91.60 - C91.62, C91.90 - C91.92, C91.A0 - C91.A2, or C91.Z0 - C91.Z2 Effective 8/9/12 (FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 204.00 - 204.92. Minimum age restriction of 16 years. |
| Injection, obinutuzumab, 25 mg. | Gazyva | Antineoplastic | Х | х | х | | | | | | | | | Closed 12/31/14. See J9301 after this date. Effective 11/1/13(FDA approval date). Cost invoice with NDC required. ICD-9 diagnosis restriction of 204.10. Minimum age restriction of 16 years. Service limitmaximum dosage of 1000 mg. applies. |
| Injection, Coagulation factor XIIIA, recombinant | Tretten | Antihemophilic | х | Х | х | | | | | | | | | Closed 12/31/14. See J7181 after this date. Effective 12/23/13(FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 286.3. Outpatient hospital must use C9134 after 7/1/14. |
| Injection, Elosulfase alfa, 5 mg./5 ml. | Vimizim | Enzymatic | Х | Х | х | | | | | | | | | Closed 12/31/14. See J1322 after this date. Effective 2/14/14(FDA approval). Cost invoice with NDC required. ICD-9 diagnosis restriction of 277.5. Minimum age restriction of 5 years. Outpatient hospital must use C9022 after 7/1/14. |

Disclaimer: Coverage depends on the NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service.

| Description | Brand Name | Category | * AC OP | *CAH OP | * P | *MW | * NP | *OPH | * POD | *DC | *HI | * IDTF | *ASC | Special Instructions |
|---|---------------|------------------------|------------|------------|-----|-----|------|------|-------|-----|-----|--------|------|---|
| Injection, Coagulation factor IX, (recombinant), Fc Fusion protein | Alprolix | Antihemophilic | X | X | Х | | | | | | | | | Closed 12/31/14. See J7201 after this date. Effective 3/28/14(FDA approval). Cost invoice with NDC required. Restricted to ICD-9 diagnosis of 286.1. Outpatient hospital must use C9135 after 10/1/15. |
| Injection, siltuximab, 100 mg. | Sylvant | Monoclonal antibody | х | Х | Х | | | | | | | | | Closed 12/31/15. See J2860 after this date. Effective 10/1/2015 ICD-10 diagnosis codes R59.0, R59.1 or R59.9 Effective 4/22/14(FDA approval) Cost invoice with NDC required. Restricted to ICD-9 diagnosis of 785.6. Minimum age restriction of 16 years. Outpatient hospital must use C9455 after 7/1/15. |
| Injection, C1 esterase inhibitor (recombinant) | Ruconest | Enzymatic | Х | Х | Х | | | | | | | | | Closed 12/31/15. See J0596 after this date. Effective 10/1/2015 ICD-10 diagnosis codes D81.810 or D84.1 Effective 7/16/14(FDA approval). Cost invoice with NDC required. Restricted to ICD-9 diagnosis of 277.6. Minimum age restriction of 13 years. hospital must use C9445 after 4/1/15. |
| Injection, Coagulation factor VIII, (recombinant), Fc Fusion protein | Eloctate | Antihemophilic | X | X | X | | | | | | | | | Closed 3/31/15. See Q9975, effective 4/1/15. Effective 6/6/14(FDA approval). Cost invoice with NDC required. Restricted to ICD-9 diagnosis of 286.0. Minimum age restriction of 2 years. Outpatient hospital must use C9136 after 1/1/15. |
| Injection, belinostat 500 mg. | Beleodaq | Antineoplastic | X | X | Х | | | | | | | | | Closed 12/31/15. See J9032 after this date. Effective 10/1/2015 ICD-10 diagnosis codes C84.40 - C84.49 Effective 7/3/14(FDA approval). Cost invoice with NDC required. Restricted to ICD-9 diagnosis of 202.7. Minimum age restriction of 16 years. patient hospital must use C9442 after 1/1/15. |
| Injection, vedolizumab, 300 mg. | Entyvio | Monoclonal antibody | X | x | X | | | | | | | | | Closed 12/31/15. See J3380 after this date. Effective 10/1/2015 ICD-10 diagnosis codes K50.00, K50.011 - K50.014, K50.018, K50.019, K50.10, K50.111 - K50.114, K50.118, K50.119, K50.80, K50.811 - K50.814, K50.818, K50.819, K50.90, K50.911 - K50.914, K50.918, K50.919, K51.00, K51.011 - K51.014, K51.018, K51.019, K51.20, K51.211 - K51.214, K51.218, K51.219, K51.30, K51.311 - K51.314, K51.318, K51.319, K51.40, K51.411 - K51.414, K51.418, K51.419, K51.50, K51.511 - K51.514, K51.518, K51.519, K51.80, K51.811 - K51.814, K51.818, K51.819, K51.90, K51.911 - K51.914, K51.918 or K51.919 Effective 5/20/14(FDA approval). Cost invoice with NDC required. Restricted to ICD-9 diagnosis of 555.0 - 556.9. Minimum age restriction of 16 years. Service limit of 300 mg. daily applies. Outpatient hospital must use C9026 after 10/1/14. |

Disclaimer: Coverage depends on the NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service.

| Description | Brand Name | Category | * AC OP | *CAH OP | * P | *MW | * NP | *OPH | * POD | *DC | *HI | * IDTF | *ASC | Special Instructions |
|--|---------------|----------------|------------|------------|-----|-----|------|------|-------|-----|-----|--------|------|--|
| Injection, ramucirumab, 100 mg./10 ml. | Cyramza | Antineoplastic | X | x | X | | | | | | | | | Closed 12/31/15. See J9308 after this date. Effective 10/1/2015 ICD-10 diagnosis codes C16.0 - C16.6, C16.8, C16.9, C18.0 - C18.9, C19, C20, C21.0 - C21.2, C21.8, C33, C34.00 - C34.02, C34.10 - C34.12, C34.2, C34.30 - C34.32, or C34.80 - C34.82 Effective 4/14/15, ICD-9 diagnosis of 153.0 - 154.8 added. Effective 12/12/14, ICD-9 diagnosis restriction of 162.0 - 162.8 added. Effective 4/21/14(FDA approval). Cost invoice with NDC required. Restricted to ICD-9 diagnosis of 151.0 - 151.9. Minimum age restriction of 16 years. Outpatient hospital must use C9025 after 10/1/14. |
| Injection, oritivancin diphosphate, 400 mg. | Orbactiv | Anti-infective | x | X | X | | | | | | | | | Closed 12/31/15. See J2407 after this date. Effective 10/1/2015 ICD-10 diagnosis codes B78.1, K12.2, L01.00 - L01.03, L01.09, L01.1 - L02.03, L02.11 - L02.13, L02.211 - L02.216, L02.219, L02.221 - L02.226, L02.229, L02.231 - L02.236, L02.239, L02.31 - L02.33, L02.411 - L02.416, L02.419, L02.421 - L02.426, L02.429, L02.431 - L02.436, L02.439, L02.511, L02.512, L02.519, L02.521, L02.522, L02.529, L02.531, L02.532, L02.539, L02.611, L02.612, L02.619, L02.621, L02.622, L02.629, L02.631, L02.632, L02.639, L02.811, L02.818, L02.821, L02.828, L02.831, L02.838, L02.91 - L02.93, L03.011, L03.012, L03.019, L03.021, L03.022, L03.029, L03.031, L03.032, L03.039, L03.041, L03.042, L03.049, L03.111 - L03.116, L03.119, L03.121 - L03.126, L03.129, L03.211, L03.212, L03.221, L03.222, L03.311 - L03.316, L03.317, L03.319, L03.321 - L03.326, L03.327, L03.329, L03.811, L03.818, L03.891, L03.898, L03.90, L03.91, L04.0 - L04.3, L04.8, L04.9, L05.01, L05.02, L05.91, L05.92, L08.0, L08.81, L08.82, L08.89, L08.9, L88, L92.8, L98.0 or L98.3 Effective 8/6/14 (FDA approval). Cost invoice with NDC required. Restricted to ICD-9 diagnosis of 680.0 - 686.9. Minimum age restriction of 18 years. Outpatient hospital must use C9444 after 1/1/15. |
| Injection, pembrolizumab, 50 mg. | Keytruda | Antineoplastic | x | X | X | | | | | | | | | Closed 12/31/15. See J9271 after this date. Effective 10/1/2015 ICD-10 diagnosis codes C00.5, C43.0, C43.10 - C43.12, C43.20, C43.22, C43.30, C43.31, C43.39, C43.4, C43.51, C43.52, C43.59 - C43.62, C43.70 - C43.72, C43.8, C43.9, C44.00 - C44.02, C44.09, C44.101, C44.102, C44.109, C44.111, C44.112, C44.119, C44.121, C44.122, C44.129, C44.191, C44.192, C44.199, C44.201, C44.202, C44.209, C44.211, C44.212, C44.219, C44.221, C44.222, C44.229, C44.291, C44.292, C44.299, C44.300, C44.301, C44.309, C44.310, C44.311, C44.319, C44.320, C44.321, C44.329, C44.390, C44.391, C44.399, C44.40 - C44.42, C44.49, C44.500, C44.501, C44.509 - C44.511, C44.519 - C44.521, C44.529, C44.590, C44.591, C44.599, C44.601, C44.602, C44.609, C44.611, C44.612, C44.619, C44.621, C44.622, C44.629, C44.691, C44.692, C44.699, C44.701, C44.702, C44.709, C44.711, C44.712, C44.719, C44.721, C44.722, C44.729, C44.791, C44.792, C44.799, C44.80 - C44.82, C44.89 - C44.92, C44.99, C4A.4, D03.0, D03.10 - D03.12, D03.20 - D03.22, D03.30, D03.39, D03.4, D03.51, D03.52, D03.59, D03.60 - D03.62, D03.70 - D03.72, D03.8 or D03.9 Effective 9/4/14(FDA approval). Cost invoice with NDC required. Restricted to ICD-9 diagnosis of 172.0 - 172.9, 173.0 - 173.9. Minimum age restriction of 16 years. hospital must use C9027 after 1/1/15. |

Disclaimer: Coverage depends on the NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service.

| Description | Brand Name | Category | * AC OP | *CAH OP | * P | *MW | * NP | *OPH | * POD | *DC | *HI | * ID | rf * | ASC | Special Instructions |
|---|---------------|----------------|------------|------------|-----|-----|------|------|-------|-----|-----|------|------|-----|--|
| Injection, Antihemophilic factor IX, (recombinant), porcine | Obizur | Antihemophilic | x | X | x | | | | | | | | | | Closed 12/31/15. See J7188 after this date. Effective 10/1/2015 ICD-10 diagnosis codes D68.32 or D68.4 Effective 10/23/14(FDA approval). Cost invoice with NDC required. Restricted to ICD-9 diagnosis of 286.7. Minimum age restriction of 16 years. |
| Injection, dalbavancin HCI, 500 mg. | Dalvance | Anti-infective | x | x | X | | | | | | | | | | Closed 12/31/15. See J0875 after this date. Effective 10/1/2015 ICD-10 diagnosis codes B78.1, K12.2, L01.00 - L01.03, L01.09, L01.1 - L02.03, L02.11 - L02.13, L02.211 - L02.216, L02.219, L02.221 - L02.226, L02.229, L02.231 - L02.236, L02.239, L02.31 - L02.33, L02.411 - L02.416, L02.419, L02.421 - L02.426, L02.429, L02.431 - L02.436, L02.439, L02.511, L02.512, L02.519, L02.521, L02.522, L02.529, L02.531, L02.532, L02.539, L02.611, L02.612, L02.619, L02.621, L02.622, L02.629, L02.631, L02.632, L02.639, L02.811, L02.818, L02.821, L02.828, L02.831, L02.838, L02.91 - L02.93, L03.011, L03.012, L03.019, L03.021, L03.022, L03.029, L03.031, L03.032, L03.039, L03.041, L03.042, L03.049, L03.111 - L03.116, L03.119, L03.121 - L03.126, L03.212, L03.221, L03.221, L03.222, L03.311 - L03.316, L03.317, L03.319, L03.321 - L03.326, L03.327, L03.329, L03.811, L03.818, L03.891, L03.898, L03.90, L03.91, L04.0 - L04.3, L04.8, L04.9, L05.01, L05.02, L05.91, L05.92, L08.0, L08.81, L08.82, L08.89, L08.9, L88, L92.8, L98.0 or L98.3 Effective 5/23/14 (FDA approval). Cost invoice with NDC required. Restricted to ICD-9 diagnosis of 680.0 686.9. Minimum age restriction of 16 years. Outpatient hospital must use C9443 aftter 1/1/15. |
| Injection, nivolumab, 10 mg./ml. | Opdivo | Antineoplastic | x | x | x | | | | | | | | | | Closed 12/31/15. See J9299 after this date. Effective 11/23/15, C64.1, C64.2, C64.9 added. Effective 10/1/2015 ICD-10 diagnosis codes C00.5, C33, C34.00 - C34.02, C34.10 - C34.12, C34.2, C34.30 - C34.32, C34.80 - C34.82, C43.0, C43.10 - C43.12, C43.20 - C43.22, C43.30, C43.31, C43.39, C43.4, C43.51, C43.52, C43.59 - C43.62, C43.70 - C43.72, C43.8, C43.9, C44.00 - C44.02, C44.09, C44.101, C44.102, C44.109, C44.111, C44.112, C44.119, C44.121, C44.122, C44.129, C44.191, C44.192, C44.199, C44.201, C44.202, C44.209, C44.211, C44.212, C44.219, C44.221, C44.222, C44.229, C44.291, C44.292, C44.299, C44.300, C44.301, C44.309, C44.310, C44.311, C44.319, C44.320, C44.321, C44.329, C44.390, C44.391, C44.399, C44.40 - C44.42, C44.49, C44.500, C44.501, C44.509 - C44.511, C44.519 - C44.521, C44.529, C44.629, C44.691, C44.692, C44.699, C44.701, C44.702, C44.709, C44.711, C44.712, C44.719, C44.721, C44.722, C44.729, C44.791, C44.792, C44.799, C44.80 - C44.82, C44.89 - C44.92, C44.99, C4A.4, D03.0, D03.10 - D03.12, D03.20 - D03.22, D03.30, D03.39, D03.4, D03.51, D03.52, D03.59, D03.60 - D03.62, D03.70 - D03.72, D03.8 or D03.9 Effective 3/4/15, diagnosis restriction of 162.0 - 162.8 added. Effective 12/22/14 (FDA approval). Cost invoice with NDC required. Restricted to ICD-9 diagnosis of 172.0 - 172.9 or 173.0 - 173.9. Minimum age restriction of 16 years. Notipatian must use C9453 after 7/1/15. |

Disclaimer: Coverage depends on the NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service.

| Description | Brand Name | Category | * AC OP | *CAH OP | * P | *MW | * NP | *OPH | * POD | *DC | *HI | * IDTF | *AS | Special Instructions |
|---|------------------|---------------------------------|------------|------------|-----|-----|------|------|-------|-----|-----|--------|-----|--|
| Injection, peramivir 200 mg./20 ml. | Rapivab | Anti-influenza | х | х | Х | | х | | | | | | | Closed 12/31/15. See J2547 after this date. Effective 10/1/2015 ICD-10 diagnosis codes J09.X1, J09.X2, J09.X3, J09.X9, J10.00, J10.01, J10.08, J10.1, J10.2, J10.81, J10.89, J11.00, J11.08, J11.1, J11.2, J11.81, or J11.89 Effective 12/19/14 (FDA approval). Cost invoice with NDC required. Restricted to ICD-9 diagnosis of 487.0 - 487.8 or 488. Minimum age restriction of 18 years. Service limit of 600 mg. per day applies. Outpatient hospital must use C9451 after 4/1/15. |
| Injection, blinatumomab, 35 mcg. | Blincyto | Antineoplastic | х | Х | Х | | | | | | | | | Closed 12/31/15. See J0939 after this date. Effective 10/1/2015 ICD-10 diagnosis codes C91.00 - C91.02 Effective 12/3/14 (FDA approval). Cost invoice with NDC required. Restricted to ICD-9 diagnosis of 204.00 - 204.02. Outpatient hospital must use C9449 after 4/1/1/5. |
| Injection, alemtuzumab, 12 mg./1.2 ml. | Lemtrada | Multiple schlerosis agent | Х | х | х | | х | | | | | | | Closed 9/30/15. See Q9979 after this date. Effective 11/14/14 (FDA aproval). Cost invoice with NDC required. Restricted to ICD-9 diagnosis of 340. Minimum age restriction of 17 years. |
| Injection, ceftolozane 50 mg. and tazobactam 25 mg. | Zerbaxa | Anti-infective | х | Х | x | | Х | | | | | | | Closed 12/31/15. See J0695 after this date. Effective 12/19/14 (FDA approval). Cost invoice with NDC required. Minimum age restriciton of 18 years Outpatient hospital must use C9452 after 4/1/15. |
| Fluocinolone acetonide, 0.19 mg. intravitreal implant | Iluvien | Anti- inflammatory | х | Х | х | | | | | | | | | Closed 12/31/15. See J7313 after this date. Effective 10/1/2015 ICD-10 diagnosis code E11.311 Effective 9/26/14 (FDA approval). Cost invoice with NDC required. Restricted to ICD-9 diagnosis of 362.07. Outpatient hospital must use C9450 after 4/1/15. |
| Injection, ceftazidime- avibactam 2.5 G | Avycaz | Anti-infective | Х | Х | Х | | х | | | | | | | Closed 12/31/15. See J0714 after this date. Effective 2/25/15 (FDA approval). Cost invoice with NDC required. Minimum age restriction of 18 years. |
| Injection, Coagulation Factor IX, (recombinant) | lxinity | Anti-hemophilic | X | Х | х | | | | | | | | | Effective 4/27/15 (FDA approval). Cost invoice with NDC required. Restricted to diagnosis of ICD-9 286.1 or ICD-10 D67. Minimum age restriction of 12 years. |
| Injection, propofol 10 mg. | Diprivan | Sedating agent | Х | Х | х | | | | | | | | | Closed 12/31/14. See J2704 after this date. Effective 1/1/14. Cost invoice with NDC required. |
| Injection, isavuconazoniu m sulfate, 1 mg. | Cresemba vial | Anti-infective | х | Х | x | | | | | | | | | Closed 12/31/15. See 1833 after this date. Effective 3/6/15 (FDA approval). Cost invoice with NDC required. Restricted to diagnosis of ICD-9 117.3 or ICD-10 B44.0, B44.1, B44.2, B44.7, B44.89, B44.9, B48.4. Minimum age restriction of 18 years. Outpatient hospital use C9456 after 10/1/15. |

Disclaimer: Coverage depends on the NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service.

| Description | Brand Name | Category | * AC OP | *CAH OP | * P | *MW | * NP | *OPH | * POD | *DC | *HI | * IDTF | *ASC | Special Instructions |
|---|---------------|-----------------|------------|------------|-----|-----|------|------|-------|-----|-----|--------|------|---|
| Injection, dinutuximab, 17.5 mg./5 ml. | Unituxin | Anti-neoplastic | Х | X | Х | | | | | | | | | Effective 3/10/15 (FDA approval). Cost invoice with NDC required. Restricted to diagnosis of ICD-9 194.0 - 194.9 or ICD-10 C74.00, C74.01, C74.02, C74.10, C74.11, C74.12, C74.90, C74.91, C74.92, C75.0, C75.1, C75.2, C75.3, C75.4, C75.5, C75.8, C75.9. |
| Injection, Coagulation Factor X, human | Coagadex | Anti-hemophilic | х | Х | Х | | | | | | | | | Closed 12/31/16. See J7175 after this date. Effective 10/20/15 (FDA approval). Cost invoice with NDC required. Restricted to diagnosis of ICD-10 D68.2. Minimum age restriction of 12 years. |
| Injection, Antihemophilic factor VIII, (recombinant) | Nuwiq | Anti-hemophilic | Х | X | x | | | | | | | | | Closed 12/31/16. See J7209 after this date. Effective 9/4/15 (FDA approval). Cost invoice with NDC required. Restricted to diagnosis of ICD-9 286.0 or ICD-10 D66. Minimum age of 2 years. Outpatient hospital use C9138 after 4/1/16. |
| Injection, mepolizumab, 100 mg. | Nucala | Anti-asthmatic | Х | Х | x | | Х | | | | | | | Closed 12/31/16. See J2182 after this date. Effective 11/4/15 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 diagnosis of J45.50. Minimum age of 12 years. Outpatient hospital use C9473 after 4/1/16. |
| Injection, talimogene laherparepvec | Imlygic | Anti-neoplastic | х | Х | Х | | | | | | | | | Closed 12/31/16. See J9325 after this date. Effective 10/27/15 (FDA approval). Cost invoice with NDC required. Minimum age of 16 years. Outpatient hospital use C9472 after 4/1/16. |
| Injection, trabectedin 1 mg. | Yondelis | Anti-neoplastic | х | Х | х | | | | | | | | | Closed 12/31/16. See J9352 after this date. Effective 10/23/15 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 diagnosis of C49.9. Minimum age of 16 years. Outpatient hospital use C9480 after 7/1/16. |
| Injection, irinotecan liposomal 43 mg./10 ml. | Onivyde | Anti-neoplastic | Х | Х | Х | | | | | | | | | Closed 12/31/16. See J9205 after this date. Effective 10/22/15 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 diagnosis of C25.0, C25.1, C25.2, C25.3, C25.4, C25.7, C25.8, C25.9. Minimum age of 16 years. Outpatient hospital use C9474 after 4/1/16. |
| Injection, Antihemophilic factor VIII, (recombinant) | Adynovate | Anti-hemophilic | Х | X | x | | | | | | | | | Closed 12/31/16. See J7207 after this date. Effective 11/13/15 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 diagnosis of D66. Minimum age of 12 years. Outpatient hospital use C9137 after 4/1/16. |
| Injection, elotuzumab | Empliciti | Anti-neoplastic | х | Х | х | | | | | | | | | Closed 12/31/16. See J9176 after this date. Effective 11/30/15 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 diagnosis of C90.00, C90.01, C90.02. Minimum age of 16 years. Outpatient hospital use C9477 after 7/1/16. |
| Injection, necitumumab 800 mg./50 ml. | Portrazza | Anti-neoplastic | Х | X | x | | | | | | | | | Closed 12/31/16. See J9295 after this date. Effective 11/24/15 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 diagnosis of C34.01, C34.02, C34.11, C34.12, C34.2, C34.31, C34.32, C34.81, C34.82, C34.91, C34.92, C38.4, C78.01, C78.02. Minimum age of 16 years. Service limitation of 800 mg. daily applies. Outpatient hospital use C9475 after 4/1/16. |

Disclaimer: Coverage depends on the NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service.

| Description | Brand Name | Category | * AC OP | *CAH OP | * P | *MW | * NP | *OPH | * POD | *DC | *HI | * IDTF | *ASC | Special Instructions |
|--|---------------|-----------------|------------|------------|-----|-----|------|------|-------|-----|-----|--------|------|---|
| Injection, sebelipase alfa, 20 mg./10 ml. | Kanuma | Enzymatic | Х | X | х | | | | | | | | | Closed 12/31/16. See J2840 after this date. Effective 12/8/15 (FDA approval). Cost invoice with NDC required. Outpatient hospital use C9478 after 7/1/16. |
| Injection, daratumumab, 100 mg./5 ml. | Darzalex | Anti-neoplastic | Х | X | x | | | | | | | | | Closed 12/31/16. See J9145 after this date. Effective 11/16/15 (FDA approval). Cost invoce with NDC required. Restricted to ICD-10 C90.02. Minimum age restriction of 16 years. Service limit of 2100 mg. daily applies. Outpatient hospital use C9145 after 7/1/16. |
| Injection, antihemophilia factor VIII, recombinant, single-chain | Afstyla | Anti-hemophilic | Х | Х | X | | | | | | | | | Effective 5/25/16 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 D66. Outpatient hospital use C9140 after 1/1/17. |
| Injection, defibrotide sodium, 200 mg./2.5 ml. | Defitelio | Thrombolytic | Х | X | x | | | | | | | | | Effective 3/30/16 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 K76.5. Service limit of 4000 mg. daily applies. |
| Injection, ciprofloxacin otic susp., 6% vial | Otiprio | Anti-infective | Х | x | X | | Х | | | | | | | Closed 12/31/16. See J7342 after this date. Effective 12/10/15 (FDA approval). Cost invoice with NDC required. Covered to Ambulatory Surgical Centers (ASC). Outpatient hospital use C9479 after 7/1/16. |
| Injection, reslizumab 100 mg./10 ml. | Cinqair | Anti-asthmatic | Х | Х | Х | | Х | | | | | | | Closed 12/31/16. See J2786 after this date. Effective 3/23/16 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 J45.50. Minimum age of 18 years. Outpatient hospital use C9481 after 10/1/16. |
| Injection, atezolizumab 1200 mg./20 ml. | Tecentriq | Anti-neoplastic | х | Х | x | | | | | | | | | Closed 12/31/17. See J9022 after this date. Effective 10/18/16, approved ICD-10 diagnoses of C34.00 - C34.92. Effective 5/18/16 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 C65.1, C65.2, C65.9, C66.1, C66.2, C66.9, C67.0, C67.1, C67.2, C67.3, C67.4, C67.5, C67.6, C67.7, C67.8, C67.9, C68.0. Minimum age restriction of 16 years. Service limit of 1200 mg. daily applies. Outpatient hospital use C9483 after 10/1/16. |
| Injection, coagulation Factor IX, albumin fusion protein | Idelvion | Anti-hemophilic | x | Х | x | | | | | | | | | Closed 12/31/16. See J7202 after this date. Effective 3/4/16 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 D67. Outpatient hospital use C9139 after 10/1/16. |

Disclaimer: Coverage depends on the NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service.

| Description | Brand Name | Category | * AC OP | *CAH OP | * P | *MW | * NP | *OPH | * POD | *DC | *HI | * IDTF | *ASC | Special Instructions |
|---|---------------|---------------------------------|------------|------------|-----|-----|------|------|-------|-----|-----|--------|------|--|
| Buprenorphine implant, 74.2 mg. | Probuphine | Anti- dependence | | | X | | | | | | | | | Closed 12/31/16. See J0570 after this date. Effective 5/26/16 (FDA approval). Restricted to ICD-10 diagnosis F11.20, F11.21, F11.229, F11.259, F11.23, F11.93. Minimum age of 16 years. Service limit of 8 units per year applies. Must have demonstrated six months compliance with oral buprenorphine products. Prescriber must be a WV Medicaid Approved Prescriber of buprenorphine/buprenorphine-naloxone products. |
| Nusinersen 12 mg./5 ml. injection | Spinraza | Protein Deficiency agent | х | Х | | | | | | | | | | Closed, effective 6/30/17. Refer to Point of Sale (POS) pharmacy coverage. Effective 12/23/16 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 diagnosis of G12.0 or G12.1. |
| Intrauterine, levonorgestrel 19.5 mg. | Kyleena | Contraceptive | Х | Х | х | Х | х | | | | | | | Closed, effective 6/30/17. See Q9984 after this date. Effective 9/16/16 (FDA approval). Cost invoice with NDC required. Service limit of once every five years applies. |
| Eteplirsen 100 mg./2 ml. injection | Exondys 51 | Anti-neoplastic | Х | Х | | | | | | | | | | Closed 12/31/17. See J1428 after this date. Effective 9/19/16 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 diagnosis G71.0. Outpatient hospital use C9484 after 4/1/17. |
| Olaratumab 500 mg./50 ml. injection | Lartruvo | Anti-neoplastic | Х | Х | Х | | | | | | | | | Closed 12/31/17. See J0985 after this date. Effective 10/19/16 (FDA approval). Cost invoice with NDC required. Outpatient hospital use C9483 after 4/1/17. |
| Injection, ocrelizumab 300 mg./10 ml. | Ocrevus | Multiple schlerosis agent | x | Х | Х | | | | | | | | | Closed 12/31/17. See J2350 after this date. Effective 3/28/17 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 G35. Service limit of 600 mg. applies. Outpatient hospital use C9485 after 4/1/1/7. |
| Injection, avelumab, 10 mg. | Bavencio | Anti-neoplastic | Х | X | x | | | | | | | | | Closed 12/31/17. See J9023 after this date. Effective 3/23/17 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 C4A.0, C4A.10 - C4A.12, C4A.20 - C4A.22, C4A.30 - C4A.39, C4A.4, C4A.51 - C4A.59, C4A.60 - C4A.62, C4A.70 - C4A.72, C4A.8, C4A.9. Minimum age restriction of 12 years. Outpatient hospital use C9491 after 10/1/17. |
| Injection, durvalumab, 10 mg. | Imfinzi | Anti-neoplastic | X | X | x | | | | | | | | | <i>Closed 12/31/18. See J9173 after this date.</i> Effective 2/16/18, NSCLC ICD-10 diagnosis added: C33, C34.01, C34.02, C34.11, C34.12, C34.2, C34.31, C34.32, C34.81, C34.82, C34.91, C34.91. Effective 5/1/17 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 C65.1, C65.2, C66.1, C66.2, C67 - C67.9, C68.0, C68.8. Minimum age of 16 years. Outpatient hospital use C9492 after 10/1/17. |
| Injection, edaravone, 1 mg. | Radicava | Anti-neoplastic | Х | X | x | | | | | | | | | Closed 12/31/18. See J1301 after this date. Effective 5/5/17 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 G12.21. Minimum age of 16 years. Outpatient hospital use C9493 after 10/1/17. |

Disclaimer: Coverage depends on the NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service.

| Description | Brand Name | Category | * AC OP | *CAH OP | * P | *MW | * NP | *OPH | * POD | *DC | *HI | * IDTF | *ASC | Special Instructions |
|--|---------------|---------------------------|------------|------------|-----|-----|------|------|-------|-----|-----|--------|------|---|
| Injection, bezlotoxumab 10 mg. | Zinplava | Anti-infective | х | Х | х | | | | | | | | | Closed 12/31/17. See J0565 after this date. Effective 10/21/16 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 A04.71, A04.72. Minimum age of 18 years. Outpatient hospital use C9490 after 7/1/17. |
| Injection, etelcalcetide, 0.1 mg. | Parsabiv | Hyperparathyro idism | х | Х | X | | | | | | | | | Closed 12/31/17. See J0606 after this date. Effective 2/17/17 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 E21.1. Miniimum age of 16 years. |
| Injection, cerliponase alfa, 1 mg. | Brineura | Liposome deficiency | X | Х | Х | | | | | | | | | Closed 12/31/18. See J0567 after this date. Effective 4/27/17 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 E75.4. Minimum age of 3 years. Outpatient hospital use C9014 after 1/1/18. |
| Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine | Vyxeos | Antineoplastic | х | Х | х | | | | | | | | | <i>Closed 12/31/18. See J9154 after this date.</i> Effective 8/3/17 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 C92.00 - C92.02. Minimum age of 16 years. Outpatient hospital use C9024 after 1/1/18. |
| Injection, inotuzumab ozogamicin, 0.1 mg. | Besponsa | Antineoplastic | х | X | х | | | | | | | | | Closed 12/31/18. See J9229 after this date. Effective 8/17/17 (FDA approval). Cost invoice with NDC required. Rrestricted to ICD-10 C91.00 - C91.02. Minimum age of 16 years. Outpatient hospital use C9028 after 1/1/18. |
| Injection, immune globulin, 100 mg | Cuvitru | Immunologic | х | Х | х | | | | | | | | | Closed 12/31/17. See J1555 after this date. Effective 7/24/17 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 D83.0 - D83.9. Minimum age of 2 years. |
| Injection, benralizumab 30 mg./ml. | Fasenra | Anti-asthmatic | Х | Х | Х | | | | | | | | | <i>Closed 12/31/18. See J0517 after this date.</i> Effective 11/14/17 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 J45.50. Minimum age of 12 years. Outpatient hospital use C9466 afte r 4/1/18. |
| Injection, sugammadex sodium 100 mg./ml. | Bridion | Relaxant binding agent | Х | Х | Х | | | | | | | | X | Effective 12/15/15 (FDA approval). Cost invoice with NDC required. |
| Injection, delafloxacin 300 mg. vial | Baxdela | Anti-infective | Х | Х | Х | | Х | | | | | | | Effective 6/19/17 (FDA approval). Cost invoice with NDC required. Outpatient hospital use C9462 after 4/1/18. |

Disclaimer: Coverage depends on the NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service.

| | Brand Name | Category | * AC OP | *CAH OP | * P | *MW | * NP | *OPH | * POD | *DC | *HI | * IDTF | *ASC | Special Instructions |
|---|-------------------|---------------------------|------------|------------|-----|-----|------|------|-------|-----|-----|----------|------|---|
| Injection, rituximab hyaluronidase | Rituxan Hycela | Antineoplastic | X | X | × | | | | | | | | | <i>Closed 12/31/18. See J9311 after this date.</i> Effective 6/22/17 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 diagnosis of C82.00 - C82.99, C83.30 - C83.39, C91.10, C91.12. Minimum age of 16 years. Outpatient hospital use C9467 after 4/1/18. |
| Injection, triamcinolone acetonide 32 mg. | Zilretta | Anti- inflammatory | X | х | x | | х | | | | | | | Closed 6/30/18. See Q9993 after this date. Effective 10/6/17 (FDA approval). Cost inivoice with NDC required. Restricted to ICD-10 diagnosis of M17.1 - M17.9. Once yearly service limit applies. Outpatient hospital use C9469 after 4/1/18. |
| Injection, copanlisib 1 mg. | Aliqopa | Antineoplastic | X | х | x | | | | | | | | | Closed 12/31/18. See J9057 after this date. Effective 9/4/17 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 diagnosis of C82.00 - C82.99. Minimum age of 16 years. Service limit of 60 mg. daily applies. Outpatient hospital use C9030 after 7/1/18. |
| Injection, burosumab-twza | Crysvita | Growth factor antibody | X | x | х | | | | | | | | | Closed 12/31/18. See J0584 after this date. Effective 4/17/18 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 diagnosis E83.31. Service limit of 90 mg. daily applies. |
| Injection, mogamulizumab- kpkc, 20 mg./5 ml. | Poteligeo | Antineoplastic | X | Х | x | | | | | | | | | Effective 8/8/18 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 C84.01 - C84.09, C84.11 - C84.19. Out patient hospital use C9038 after 1/1/19. |
| Injection, triptorelin extended release, 3.75 mg | Triptodur | Gonadotropin | X | x | × | | | | | | | | | <i>Closed 12/31/18. See J3316 after this date.</i> Effective 6/29/17 (FDA approval). Cost invoice with NDC required. Restricted to ICD-10 E30.1 Minimum age of 2 years. Service limit of 6 units every 23 weeks applies. |
| Injection, patisiran, 0.1 mg | Onpattro | Amyloidosis agent | х | x | × | | | | | | | | | Effective 8/10/18 (FDA approval). Restricted to ICD-10 E85.1. Minimum age of 18 years. Service limit of 300 units. Outpatient hospital use C9036 after 1/1/19. |
| | | | | | | | | | | | | <u>.</u> | | |
| *AC/OP-Acute Ca | | | | | | | | | | | | | | |
| *CAH/OP-Critical | Access/Out | Patient Hospital | | | | | | | | | | | | |
| *P - Physician | <u></u> | | | | | | | | | | | | | |
| *NP - Nurse Prac | | | | | | | | | | | | | - | |
| *MW - Nurse Mid | | | <u> </u> | | | | | | | | | | | 1 |
| OPH - Ophthalm | iologist | | | | | | | | | | | | | |

Disclaimer: Coverage depends on the NDC status (rebate eligible, Non-DESI, non-termed, etc) on the date of service.

| Description | Brand Name | Category | * AC OP | *CAH OP | | *MW | * NP | *OPH | * POD | *DC | *HI | * IDTF | *ASC | Special Instructions |
|-------------------|--|----------|------------|------------|--|-----|------|------|-------|-----|-----|--------|------|----------------------|
| *POD - Podiatrist | OD - Podiatrist | | | | | | | | | | | | | |
| *IDTF - Independ | IDTF - Independent Diagnostic Treatment Facility | | | | | | | | | | | | | |
| *DC - Dialysis Ce | DC - Dialysis Centers | | | | | | | | | | | | | |
| *HI - Home Infus | II - Home Infusion Centers | | | | | | | | | | | | | |